JP2001523264A5 - - Google Patents

Download PDF

Info

Publication number
JP2001523264A5
JP2001523264A5 JP1998548048A JP54804898A JP2001523264A5 JP 2001523264 A5 JP2001523264 A5 JP 2001523264A5 JP 1998548048 A JP1998548048 A JP 1998548048A JP 54804898 A JP54804898 A JP 54804898A JP 2001523264 A5 JP2001523264 A5 JP 2001523264A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998548048A
Other languages
English (en)
Japanese (ja)
Other versions
JP5033276B2 (ja
JP2001523264A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/003197 external-priority patent/WO1998050060A1/en
Publication of JP2001523264A publication Critical patent/JP2001523264A/ja
Publication of JP2001523264A5 publication Critical patent/JP2001523264A5/ja
Application granted granted Critical
Publication of JP5033276B2 publication Critical patent/JP5033276B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP54804898A 1997-05-05 1998-05-05 急性腎不全の治療 Expired - Fee Related JP5033276B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4561997P 1997-05-05 1997-05-05
US60/045,619 1997-05-05
PCT/US1998/003197 WO1998050060A1 (en) 1997-05-05 1998-05-05 Therapies for acute renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009211128A Division JP2009286802A (ja) 1997-05-05 2009-09-11 急性腎不全の治療

Publications (3)

Publication Number Publication Date
JP2001523264A JP2001523264A (ja) 2001-11-20
JP2001523264A5 true JP2001523264A5 (https=) 2005-12-02
JP5033276B2 JP5033276B2 (ja) 2012-09-26

Family

ID=21938961

Family Applications (2)

Application Number Title Priority Date Filing Date
JP54804898A Expired - Fee Related JP5033276B2 (ja) 1997-05-05 1998-05-05 急性腎不全の治療
JP2009211128A Withdrawn JP2009286802A (ja) 1997-05-05 2009-09-11 急性腎不全の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009211128A Withdrawn JP2009286802A (ja) 1997-05-05 2009-09-11 急性腎不全の治療

Country Status (11)

Country Link
US (2) US20100105621A1 (https=)
EP (1) EP0980252B1 (https=)
JP (2) JP5033276B2 (https=)
AT (1) ATE278414T1 (https=)
AU (1) AU743510B2 (https=)
CA (1) CA2289123A1 (https=)
DE (1) DE69826854T2 (https=)
DK (1) DK0980252T3 (https=)
ES (1) ES2226125T3 (https=)
PT (1) PT980252E (https=)
WO (1) WO1998050060A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612046B2 (en) 2000-01-31 2009-11-03 Uwe Waldemar Rothenpieler Method for treating kidney disorders
ES2351957T3 (es) * 2000-01-31 2011-02-14 Uwe Waldemar Rothenpieler Pax2 para tratar trastornos del riñón.
EP1407770B1 (en) * 2001-06-26 2013-06-05 Takeda Pharmaceutical Company Limited Tgf-beta superfamily production/secretion promoter
US20050272649A1 (en) * 2002-08-28 2005-12-08 Hruska Keith A Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
RU2282899C2 (ru) * 2004-01-09 2006-08-27 ГОУ ВПО Омская Государственная Медицинская Академия Способ моделирования инфекции мочевой системы
EP3147296A1 (en) * 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
US8025881B2 (en) 2006-07-21 2011-09-27 Chugai Seiyaku Kabushiki Kaisha BMP antibodies and methods of treating kidney disease using the same
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
KR101870246B1 (ko) * 2014-02-07 2018-06-22 토루 미야자키 신질환의 예방 또는 치료제

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5045452A (en) * 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
DE69031939T2 (de) 1989-03-28 1998-09-10 Genetics Institute, Inc., Cambridge, Mass. Osteoinduktive zusammensetzungen
JPH06500991A (ja) 1990-05-16 1994-01-27 ジェネティックス・インスティテュート・インコーポレイテッド 骨および軟骨誘導蛋白質
JPH0426624A (ja) 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
JPH05509086A (ja) 1990-06-22 1993-12-16 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー イミダゾールアンジオテンシン―2受容体拮抗薬による慢性腎不全の治療
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
WO1992015323A1 (en) 1991-03-11 1992-09-17 Creative Biomolecules, Inc. Protein-induced morphogenesis
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
DE69233559T2 (de) * 1991-08-30 2006-08-31 Curis, Inc., Cambridge Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
EP0601129B1 (en) 1991-08-30 2000-11-15 Creative Biomolecules, Inc. Morphogenic protein screening method
ATE192931T1 (de) * 1991-08-30 2000-06-15 Creative Biomolecules Inc Morphogen-induzierte modulation von entzündlichen antworten
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
JPH07509720A (ja) 1992-07-31 1995-10-26 クリエイティブ バイオモレキュルズ,インコーポレイテッド モルフォゲン強化栄養組成物
EP0653942B2 (en) * 1992-07-31 2007-03-07 Curis, Inc. Morphogen-induced nerve regeneration and repair
ATE287949T1 (de) 1992-07-31 2005-02-15 Stryker Corp Löslicher komplex morphogener proteine und zusammensetzungen davon
ES2114073T3 (es) 1992-09-16 1998-05-16 Creative Biomolecules Inc Regeneracion del higado inducida por morfogenes.
JPH08503198A (ja) 1992-11-03 1996-04-09 クリエイティブ バイオモレキュルズ,インコーポレイテッド Op−3誘導形態形成
JPH08510446A (ja) 1993-03-04 1996-11-05 クリエイティブ バイオモレキュルズ,インコーポレイテッド 組換え骨形成タンパク質を生成するための方法および組成物
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
JPH09509141A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ,インコーポレイテッド Igf‐iおよびigfbp‐3を投与することによる腎臓疾患処置の方法
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
KR20000064752A (ko) * 1996-03-22 2000-11-06 더 제네랄 호스피탈 코포레이션 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Similar Documents

Publication Publication Date Title
JP2000509635A5 (https=)
JP2000509637A5 (https=)
JP2000509912A5 (https=)
JP2000509942A5 (https=)
JP2000510751A5 (https=)
JP2002507976A5 (https=)
JP2002510434A5 (https=)
JP2000509587A5 (https=)
JP2001507846A5 (https=)
JP2000508866A5 (https=)
JP2002500588A5 (https=)
JP2000510793A5 (https=)
JP2000508841A5 (https=)
JP2001509710A5 (https=)
JP2000508680A5 (https=)
JP2000509804A5 (https=)
JP2000509853A5 (https=)
JP2000509755A5 (https=)
JP2001513744A5 (https=)
JP2000510969A5 (https=)
JP2000510247A5 (https=)
JP2000508836A5 (https=)
JP2000509520A5 (https=)
JP2000509818A5 (https=)
JP2000508880A5 (https=)